Loading...

Demand In Feminine Care And Incontinence Will Expand Internationally

Published
07 Nov 24
Updated
24 Sep 25
AnalystConsensusTarget's Fair Value
SEK 285.25
13.0% undervalued intrinsic discount
24 Sep
SEK 248.10
Loading
1Y
-19.7%
7D
2.1%

Author's Valuation

SEK 285.2513.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update24 Sep 25
Fair value Decreased 1.21%

Essity's consensus price target was revised slightly lower to SEK285.25 amid sector-wide pressures, a shift toward higher-margin segments lacking near-term catalysts, and concerns over potential sales shortfalls.


Analyst Commentary


  • Analysts see Essity trading at a trough valuation as it shifts focus away from tissue towards higher-margin segments, but lack near-term catalysts for upward share price movement.
  • Structural and cyclical pressures in the consumer goods sector are leading to a new paradigm that global manufacturers, including Essity, must adapt to.
  • While beauty remains an attractive category, challenges in other divisions are cited as weighing on Essity’s broader outlook.
  • Margin improvement potential exists, but some analysts expect near-term sales to miss expectations.
  • Recent sector-wide reratings and caution around incoming quarterly results are prompting more cautious or bearish revisions to price targets.

What's in the News


  • Goldman Sachs initiated coverage of Essity with a Neutral rating and a SEK 275 price target, noting shares trade at a “trough” valuation amid the company’s transition from tissue to higher-margin segments, but citing a lack of catalysts for near-term stock upside (Periodical).
  • Essity completed a share buyback program, repurchasing 2,509,728 shares (0.36% of shares outstanding) for SEK 682 million between April 24 and June 30, 2025 (Key Developments).
  • The completed share repurchase aligns with the buyback plan announced on April 28, 2025 (Key Developments).
  • The shift away from tissue products is seen as strategic for improving profitability, but the market awaits evidence of stronger growth drivers (Periodical).
  • Recent buyback activity suggests management is committed to capital returns despite limited immediate catalysts for the stock (Periodical, Key Developments).

Valuation Changes


Summary of Valuation Changes for Essity

  • The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from SEK288.75 to SEK285.25.
  • The Consensus Revenue Growth forecasts for Essity has significantly fallen from 1.6% per annum to 1.2% per annum.
  • The Net Profit Margin for Essity remained effectively unchanged, moving only marginally from 9.39% to 9.41%.

Key Takeaways

  • Strong demand in incontinence, medical, and feminine care products, coupled with innovation and brand investments, supports sustained revenue and margin growth globally.
  • Focus on sustainability, premiumization, and ongoing cost-efficiency efforts positions Essity to benefit from changing consumer preferences and improved operating leverage.
  • Structural volume and margin pressures across key segments, rising costs, and increased competition threaten Essity's growth, profitability, and pricing power in core and emerging markets.

Catalysts

About Essity
    Develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally.
What are the underlying business or industry changes driving this perspective?
  • The company continues to benefit from high and growing demand in incontinence and medical products, supported by an aging global population, which is driving stable long-term volume and revenue growth in these strategic categories.
  • Essity is experiencing strong growth in Feminine Care and Incontinence Retail segments across multiple geographies, leveraging rising healthcare standards and expanding middle class in emerging markets, supporting expectations of international revenue expansion.
  • Innovations in premium, eco-friendly, and coreless products-along with industry recognition for sustainability-position Essity to capitalize on shifting consumer preference for sustainable and higher-value tissue and hygiene products, which supports both topline growth and margin expansion.
  • Investment in brand building and marketing, as demonstrated by recent awards and increased A&P spend, is expected to drive greater brand loyalty and premiumization, bolstering future sales and improving net margins.
  • Ongoing cost-efficiency initiatives (supply chain savings, planned SG&A reductions, digitalization) are set to enhance operating leverage and protect net margins, especially as the company aims to return to higher volume growth in the face of stabilized input costs.

Essity Earnings and Revenue Growth

Essity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming Essity's revenue will grow by 1.6% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 8.6% today to 9.4% in 3 years time.
  • Analysts expect earnings to reach SEK 14.1 billion (and earnings per share of SEK 20.65) by about September 2028, up from SEK 12.3 billion today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 15.6x on those 2028 earnings, up from 14.2x today. This future PE is lower than the current PE for the GB Household Products industry at 17.2x.
  • Analysts expect the number of shares outstanding to decline by 1.22% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 4.92%, as per the Simply Wall St company report.

Essity Future Earnings Per Share Growth

Essity Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  • Persistent weak volume growth in key segments, particularly in Health & Medical and Baby Care, combined with limited ability to stimulate volumes in a challenging macroeconomic environment, poses a risk of structurally lower revenue growth than anticipated.
  • Rising SG&A costs, notably personnel and IT expenses, paired with insufficient volume growth to absorb these increases, have led to margin contraction and may continue to pressure net margins if costs are not adequately controlled.
  • Ongoing high promotional pressure and aggressive price competition, especially in segments like Baby Care and lower/mid-tier Consumer Tissue, may erode Essity's pricing power and gross margins, particularly if private label and low-cost competitors continue gaining share.
  • Sustained weakness in Professional Hygiene, exacerbated by structural shifts such as reduced restaurant and hotel traffic in North America and Europe, suggests lasting lower demand for away-from-home products, potentially limiting revenue and operating leverage in that segment.
  • Exposure to input cost volatility-including raw materials, tariffs (notably on U.S.-to-Canada exports), and distribution expenses-without commensurate ability to fully pass through these costs in all geographies and segments, could constrain earnings and net margin expansion, especially as industry consolidation intensifies pressure from retailers and distributors.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of SEK288.75 for Essity based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK330.0, and the most bearish reporting a price target of just SEK230.0.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be SEK150.1 billion, earnings will come to SEK14.1 billion, and it would be trading on a PE ratio of 15.6x, assuming you use a discount rate of 4.9%.
  • Given the current share price of SEK254.0, the analyst price target of SEK288.75 is 12.0% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives